

A **postdoctoral associate** and a **PhD student** position in the ERC-funded program «NUCDDR-Nucleolar Responses to DNA damage: Nucleolus a rising hub of genome instability» are available at the Laboratory of Biology, Medical School, University of Patras, to work on understanding the molecular mechanisms that get activated in response to ribosomal DNA (rDNA) damage. The post holders will undertake molecular, cell biology, imaging and mass spectrometry approaches to characterize the signaling pathways that get activated in response to nucleolar DNA damage.

Related publications:

Pefani, D.E, Tognoli, M.L., Pirincci Ercan, D., Gorgoulis, V., and O'Neill, E. (2018). MST2 kinase suppresses rDNA transcription in response to DNA damage by phosphorylating nucleolar histone H2B. The EMBO journal 37.

Pefani DE, Latusek R, Pires I, Grawenda AM, Yee KS, Hamilton G, van der Weyden L, Esashi F, Hammond EM, O'Neill E (2014) RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. Nature Cell Biology 16: 962-971, 961-968.

Pefani DE, Pankova D, Abraham GA, Grawenda AA, Vlahov N, Scrace S and O'Neill E (2016). TGFβ targets the Hippo pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear translocation. Molecular Cell 63: 156-166

We are looking for highly motivated candidates with a background in cell and molecular biology to work in a dynamic and highly collaborative environment.

For the **PhD position**, a BSc/MSc in Biomedical Sciences is required. Proven interest in cell and molecular biology would be an advantage.

For the **postdoctoral associate position**, a PhD alongside with a proven publication record in international peer-reviewed journals is required. Previous experience in cell signaling and/or the DNA damage response, imaging and mass spec methodologies would be an advantage.

For informal enquiries please contact Dafni Pefani at dpefani@upatras.gr.

To apply please send a CV, cover letter and contact details of 2 referees at dpefani@upatras.gr